Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00033904 · ClinicalTrials.gov registry record · Phase 3

Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer

A Phase 3 study of Renal Cell Carcinoma, sponsored by Agenus.

Completed
Registry status
Phase 3
Development phase
650
Enrollment target
20
Study locations

NCT00033904: Completed Phase 3 study of Renal Cell Carcinoma, sponsored by Agenus.

NCT00033904 is a Phase 3 study of Renal Cell Carcinoma that has completed, run by Agenus. The registered enrollment target is 650 participants, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (173% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00033904, a Phase 3 study of Renal Cell Carcinoma, has completed, sponsored by Agenus.

COMPLETED
Registry status
Phase 3
Development phase
650 participants
Enrollment target
20
Study locations

Study Summary

Determine whether patients receiving adjuvant HSPPC-96 treatment after surgically resected, locally advanced renal cell carcinoma have improved recurrence-free survival as compared to subjects with no adjuvant treatment.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG autologous human tumor-derived HSPPC-96

Study Locations (20)

Florida

  • - Boca Raton
  • - Miami
  • - Tampa

California

  • - Los Angeles
  • - San Francisco

Illinois

  • - Chicago
  • - Maywood

Alaska

  • - Anchorage

Arizona

  • - Tucson

Colorado

  • - Denver

Connecticut

  • - Farmington

Georgia

  • - Atlanta

Trial Details

FieldValue
Enrollment Target 650 participants
Start Date 2000-06
Est. Completion 2007-04
Phase Phase 3
Agenus

24 total trials

What the finished NCT00033904 record still lists

NCT00033904 is an interventional study that assigns participants to a tested intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (173% higher).

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which autologous human tumor-derived HSPPC-96 is the first listed.

NCT00033904 names 20 study sites across 16 states, led by Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT00033904 about?

NCT00033904 is a clinical study titled "Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer". Determine whether patients receiving adjuvant HSPPC-96 treatment after surgically resected, locally advanced renal cell carcinoma have improved recurrence-free survival as compared to subjects with no adjuvant treatment.

What is the current status of trial NCT00033904?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 650 participants. The study started on 2000-06. Estimated completion is 2007-04.

What conditions does trial NCT00033904 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT00033904?

The interventions under investigation include: autologous human tumor-derived HSPPC-96 (DRUG).

Who is sponsoring clinical trial NCT00033904?

This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00033904 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00033904's enrollment target sits among peer trials

650 11th of 121 higher than 111 of 121 other Renal Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02934477 · 650 participants

    Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

  • NCT04579120 · 650 participants

    Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

  • NCT04875702 · 650 participants · Phase 4

    Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

  • NCT05046600 · 650 participants

    Registry of Arthrex Hand and Wrist Products

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00033904, the US trial registry maintained by the National Library of Medicine. NCT00033904 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.